GB9523752D0 - Pharmaceutical formulations - Google Patents

Pharmaceutical formulations

Info

Publication number
GB9523752D0
GB9523752D0 GB9523752A GB9523752A GB9523752D0 GB 9523752 D0 GB9523752 D0 GB 9523752D0 GB 9523752 A GB9523752 A GB 9523752A GB 9523752 A GB9523752 A GB 9523752A GB 9523752 D0 GB9523752 D0 GB 9523752D0
Authority
GB
Grant status
Application
Patent type
Prior art keywords
pharmaceutical formulations
formulations
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GB9523752A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Ltd
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

GB9523752A 1995-11-21 1995-11-21 Pharmaceutical formulations Pending GB9523752D0 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB9523752A GB9523752D0 (en) 1995-11-21 1995-11-21 Pharmaceutical formulations

Applications Claiming Priority (28)

Application Number Priority Date Filing Date Title
GB9523752A GB9523752D0 (en) 1995-11-21 1995-11-21 Pharmaceutical formulations
AU7572196A AU709560B2 (en) 1995-11-21 1996-11-11 Pharmaceutical formulations
NZ32205396A NZ322053A (en) 1995-11-21 1996-11-11 Controlled release pharmaceutical formulation comprising an active, a low MW polyethylene oxide, HPMC and one or more enteric polymers
SK63098A SK63098A3 (en) 1995-11-21 1996-11-11 Controlled-release pharmaceutical formulation, process for its preparation and use of polyethyleneoxide
JP51936497A JPH10513481A (en) 1995-11-21 1996-11-11 Pharmaceutical preparations
CN 96198486 CN1215993A (en) 1995-11-21 1996-11-11 Pharmaceutical formulations
PCT/EP1996/005020 WO1997018814A1 (en) 1995-11-21 1996-11-11 Pharmaceutical formulations
CA 2232715 CA2232715A1 (en) 1995-11-21 1996-11-11 Pharmaceutical formulations
PL32698196A PL326981A1 (en) 1995-11-21 1996-11-11 Pharmaceutic preparations
BR9611626A BR9611626A (en) 1995-11-21 1996-11-11 pharmaceutical formulations
TR9800902T TR199800902T2 (en) 1995-11-21 1996-11-11 Pharmaceutical formulations.
EP19960938215 EP0862437A1 (en) 1995-11-21 1996-11-11 Pharmaceutical formulations
HU9903734A HU9903734A3 (en) 1995-11-21 1996-11-11 Controlled-release pharmaceutical formulations for oral administration and method for preparing this
CZ155498A CZ9801554A3 (en) 1995-11-21 1996-11-11 Pharmaceutical preparation with controlled release, process of its preparation and use of polyethylene oxide
PE00083196A PE22898A1 (en) 1995-11-21 1996-11-20 pharmaceutical formulations
TNSN96141A1 TNSN96141A1 (en) 1995-11-21 1996-11-20 Pharmaceutical formulations and process for their production
MA24397A MA26410A1 (en) 1995-11-21 1996-11-20 Pharmaceutical formulations and process for their production.
AR004335A1 AR004335A1 (en) 1995-11-21 1996-11-20 pharmaceutical formulations
YU62096A YU62096A (en) 1995-11-21 1996-11-20 Sustained released pharmaceutical formulation, the application of polyethylene oxide in them and procedure for the preparation thereof
ZA9609722A ZA9609722B (en) 1995-11-21 1996-11-20 Pharmaceutical formulations.
HRP960554A2 HRP960554A2 (en) 1995-11-21 1996-11-21 Pharmaceutical formulations
CO96061449A CO4480020A1 (en) 1995-11-21 1996-11-21 pharmaceutical formulations
AP9600883A AP718A (en) 1995-11-21 1996-11-21 A controlled-release pharmaceutical formulation for oral administration.
IS4706A IS4706A (en) 1995-11-21 1998-03-31 pharmaceutical compositions
BG10243898A BG102438A (en) 1995-11-21 1998-05-08 Medicamentous form
OA9800058A OA10687A (en) 1995-11-21 1998-05-19 Pharmaceutical formulations
MX9804008A MX9804008A (en) 1995-11-21 1998-05-20 Pharmaceutical formulations.
NO982302A NO982302A (en) 1995-11-21 1998-05-20 Pharmaceutica ° ytisk composition

Publications (1)

Publication Number Publication Date
GB9523752D0 true true GB9523752D0 (en) 1996-01-24

Family

ID=10784188

Family Applications (1)

Application Number Title Priority Date Filing Date
GB9523752A Pending GB9523752D0 (en) 1995-11-21 1995-11-21 Pharmaceutical formulations

Country Status (6)

Country Link
EP (1) EP0862437A1 (en)
JP (1) JPH10513481A (en)
CN (1) CN1215993A (en)
CA (1) CA2232715A1 (en)
GB (1) GB9523752D0 (en)
WO (1) WO1997018814A1 (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0974343B1 (en) * 1998-07-22 2004-09-29 Pharma Pass II LLC Process for manufacturing a solid metoprolol composition
DE69833671T2 (en) * 1997-12-16 2006-11-30 Pfizer Products Inc., Groton COMBINATION OF AN ALPHA-1 BLOCKING ANTAGONIST AND A CGM PDE INHIBITORS FOR THE TREATMENT OF IMPOTENCE
EP0987020A1 (en) * 1998-09-04 2000-03-22 Pharma Pass LLC Metoprolol composition and processes for manufacturing the same
US20030059467A1 (en) * 2001-09-14 2003-03-27 Pawan Seth Pharmaceutical composition comprising doxasozin
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
US6723340B2 (en) * 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US8329217B2 (en) 2001-11-06 2012-12-11 Osmotica Kereskedelmi Es Szolgaltato Kft Dual controlled release dosage form
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
EP1680078A2 (en) * 2003-10-17 2006-07-19 Ranbaxy Laboratories, Ltd. Oral matrix formulations of doxazosin
US20050255157A1 (en) * 2004-05-11 2005-11-17 Glenmark Pharmaceuticals Limited Sustained release, mucoadhesive vaginal pharmaceutical compositions
KR100574554B1 (en) * 2004-05-28 2006-04-27 한미약품 주식회사 Sustained release composition for oral administration of niacin
DE102004054054A1 (en) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg A process for preparing chiral 8- (3-amino-piperidin-1-yl) -xanthines
JP2009504796A (en) * 2005-08-22 2009-02-05 ノバルティス アクチエンゲゼルシャフト pH-dependent drug compound, a pharmaceutical composition comprising a pH adjusting agent and retarder
ES2396051T3 (en) 2006-04-26 2013-02-18 Supernus Pharmaceuticals, Inc. Controlled release preparations of oxcarbazepine having sigmoidal release profile
CN101437823B (en) 2006-05-04 2014-12-10 勃林格殷格翰国际有限公司 Polymorphs
CN100396282C (en) 2006-07-25 2008-06-25 山东省医药工业研究所 Slow released doxazosin mesilate capsule and its preparation process
WO2009114648A1 (en) 2008-03-11 2009-09-17 Depomed Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US9486526B2 (en) 2008-08-06 2016-11-08 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients inappropriate for metformin therapy
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
KR101004205B1 (en) * 2008-12-17 2010-12-24 동아제약주식회사 The controlled released pharmaceutical compsitions of udenafil for sustained release property
US9901551B2 (en) 2009-04-20 2018-02-27 Ambra Bioscience Llc Chemosensory receptor ligand-based therapies
US8828953B2 (en) 2009-04-20 2014-09-09 NaZura BioHealth, Inc. Chemosensory receptor ligand-based therapies
EP2421524B1 (en) 2009-04-20 2018-08-08 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US20110150989A1 (en) * 2009-12-22 2011-06-23 Mallinkckrodt Inc. Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans
CA2797310A1 (en) 2010-05-05 2011-11-10 Boehringer Ingelheim International Gmbh Glp-1 receptor agonist and dpp-4 inhibitor combination therapy
JP6042330B2 (en) 2010-07-09 2016-12-14 ビーエイチヴィ ファーマ、インコーポレイテッド Combinations immediate / delayed release delivery systems for a short half-life pharmaceuticals including Remogurifurojin
CN102058555A (en) * 2011-01-13 2011-05-18 北京汇诚瑞祥医药技术有限公司 Doxazosin controlled release tablet
CN102188431A (en) * 2011-05-09 2011-09-21 浙江九旭药业有限公司 Doxazosin mesylate sustained-release tablets and preparation method thereof
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US8658631B1 (en) 2011-05-17 2014-02-25 Mallinckrodt Llc Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013158928A3 (en) 2012-04-18 2013-12-12 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
EP2849755A1 (en) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
EP3110449A1 (en) 2014-02-28 2017-01-04 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4765989A (en) * 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4837111A (en) * 1988-03-21 1989-06-06 Alza Corporation Dosage form for dispensing drug for human therapy

Also Published As

Publication number Publication date Type
EP0862437A1 (en) 1998-09-09 application
WO1997018814A1 (en) 1997-05-29 application
CN1215993A (en) 1999-05-05 application
CA2232715A1 (en) 1997-05-29 application
JPH10513481A (en) 1998-12-22 application

Similar Documents

Publication Publication Date Title
GB2308545A (en) Pharmaceutical compositions
GB9305437D0 (en) Pharmaceutical formulation
GB9525838D0 (en) Pharmaceutical packaging